Business Value: januxrx.com (JANX)

Graphic logo of Janux Corp (JANX)

This Janux Therapeutics (JANX) price chart on the GURU.Markets platform, with a value of 140.15, allows for an assessment of how external factors impact the cancer immunotherapy business. Geopolitical tensions and trade restrictions could hinder product certification and raw material procurement. Simultaneously, exclusive innovation rights guarantee future market dominance. High R&D expenditures and the risk of clinical trial failures increase the company's dependence on investment.

Janux Therapeutics (JANX) - Total Company Value from 11/23/2025 to 10/30/2026

Janux Therapeutics (JANX) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Price Janux Therapeutics Inc|JANX - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization Janux Therapeutics|JANX - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Equity per Share Janux Therapeutics|JANX - Company Book Value|Market-to-Book Ratio januxrx.com|JANX - Aggregate Company Assets
- company total debt and liquidity indicators:
Debt to Equity Ratio Janux Therapeutics|JANX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio januxrx.com|JANX - Company Debts|Debts to Book Value Janux Therapeutics|JANX - Company Long-Term Debt|Company Short-Term Debt Janux Therapeutics|Immediate Liquidity januxrx.com
- earnings and valuation multiples indicators:
JANX - Net Profit
Analysis of all company metrics:Janux Therapeutics
Flagship merchandise of Janux Therapeutics, Inc.

Enterprise Value represents the total value of a business, combining market capitalization with the company's net debt. The current value of 140.15 reflects the actual cost of a full asset buyout. For the venture biotech Janux Therapeutics (JANX), this metric accounts for the potential to monopolize the cancer immunotherapy market. By analyzing the enterprise value as of today, an investor sees the value of future scalable sales. The long-term consensus links the trend of this indicator to the success of clinical trials.

Competitors of Janux Therapeutics (JANX)

Enterprise Value ImmunityBio Inc IBRX|IMCR - Total Company Value|RCUS (Arcus Corp) - Business Value|ZYME (Zymeworks Inc.) - Real Price to Acquire Entire Company|Business Value TNGX|Total Company Value Iovance Biotherapeutics, Inc.|Total Enterprise Value Immatics NV IMTX|Total Company Value Xencor Corp (XNCR)|Compass Therapeutics Corp - Business Value|Enterprise Value REPL (Replimune Group, Inc.)|LYEL - Real Price to Acquire Entire Company|IPHA - Total Company Value|Total Enterprise Value Pyxis Oncology, Inc.|cgen.com (CGEN) - Total Company Value|IOBT (IO Biotech Inc.) - Total Company Value|Total Company Value Sutro Biopharma, Inc.|Total Enterprise Value minktherapeutics.com INKT|Enterprise Value HOWL|immixbio.com (IMMX) - Full Takeover Company Value|ALX Oncology - Real Price to Acquire Entire Company|Cue Biopharma Inc. (CUE) - Total Enterprise Value|PDSB: Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash SONN (Sonnet BioTherapeutics)|MAIA: Enterprise Value|LIMN - Company Buyout Price|Total Company Value LAVA Therapeutics NV|Real Price to Acquire Entire Company NextCure Corporation (NXTC)|Total Company Value Leap Therapeutics, Inc. (LPTX)|Real Price to Acquire Entire Company intensitytherapeutics.com INTS|Sensei Biotherapeutics, Inc. - Real Price to Acquire Entire Company|Enterprise Value Theriva Biologics Inc TOVX|GRTS - Total Company Value|KA (Kineta Corp) - Business Value|NexImmune, Inc. (NEXI) - Total Company Value|Total Enterprise Value Turnstone Biologics Corp. (TSBX)|Real Price to Acquire Entire Company VCNX|HARP - Full Takeover Company Value